BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34885749)

  • 81. 6-Hydroxybenzothiophene ketones: potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) owing to favorable molecule geometry and conformational preorganization.
    Miralinaghi P; Schmitt C; Hartmann RW; Frotscher M; Engel M
    ChemMedChem; 2014 Oct; 9(10):2294-308. PubMed ID: 25044709
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Synthesis of substituted 15β-alkoxy estrone derivatives and their cofactor-dependent inhibitory effect on 17β-HSD1.
    Herman BE; Kiss A; Wölfling J; Mernyák E; Szécsi M; Schneider G
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1271-1286. PubMed ID: 31307240
    [TBL] [Abstract][Full Text] [Related]  

  • 83. 6-Substituted 3,4-dihydro-naphthalene-2-carboxylic acids: synthesis and structure-activity studies in a novel class of human 5alpha reductase inhibitors.
    Baston E; Salem OI; Hartmann RW
    J Enzyme Inhib Med Chem; 2002 Oct; 17(5):303-20. PubMed ID: 12683747
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Inhibition of 17β-HSD1: SAR of bicyclic substituted hydroxyphenylmethanones and discovery of new potent inhibitors with thioether linker.
    Abdelsamie AS; Bey E; Hanke N; Empting M; Hartmann RW; Frotscher M
    Eur J Med Chem; 2014 Jul; 82():394-406. PubMed ID: 24929290
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase.
    Qiu W; Zhou M; Mazumdar M; Azzi A; Ghanmi D; Luu-The V; Labrie F; Lin SX
    J Biol Chem; 2007 Mar; 282(11):8368-79. PubMed ID: 17166832
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC
    Abdelsamie AS; van Koppen CJ; Bey E; Salah M; Börger C; Siebenbürger L; Laschke MW; Menger MD; Frotscher M
    Eur J Med Chem; 2017 Feb; 127():944-957. PubMed ID: 27852458
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
    Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
    Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases.
    Lespérance M; Roy J; Djiemeny Ngueta A; Maltais R; Poirier D
    Steroids; 2021 Aug; 172():108856. PubMed ID: 33945801
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Some coumarins and triphenylethene derivatives as inhibitors of human testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD type 3): further studies with tamoxifen on the rat testes microsomal enzyme.
    LE Lain R; Barrell KJ; Saeed GS; Nicholls PJ; Simons C; Kirby A; Smith HJ
    J Enzyme Inhib Med Chem; 2002 Apr; 17(2):93-100. PubMed ID: 12420755
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
    Bellavance E; Luu-The V; Poirier D
    J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
    Fournier D; Poirier D; Mazumdar M; Lin SX
    Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Chalcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities.
    Le Bail JC; Pouget C; Fagnere C; Basly JP; Chulia AJ; Habrioux G
    Life Sci; 2001 Jan; 68(7):751-61. PubMed ID: 11205867
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5.
    Krazeisen A; Breitling R; Möller G; Adamski J
    Mol Cell Endocrinol; 2001 Jan; 171(1-2):151-62. PubMed ID: 11165023
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Preclinical Pharmacokinetics, Tissue Distribution and Primary Safety Evaluation of a Novel Curcumin Analogue H10 Suspension, a Potential 17β Hydroxysteroid Dehydrogenase Type 3 Inhibitor.
    Xiao L; Bei Y; Li J; Chen M; Zhang Y; Xiang Q
    Chem Pharm Bull (Tokyo); 2021 Jan; 69(1):52-58. PubMed ID: 33087639
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cinnamic acid esters as potent inhibitors of fungal 17beta-hydroxysteroid dehydrogenase--a model enzyme of the short-chain dehydrogenase/reductase superfamily.
    Gobec S; Sova M; Kristan K; Rizner TL
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3933-6. PubMed ID: 15225701
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Biochemical analyses and molecular modeling explain the functional loss of 17β-hydroxysteroid dehydrogenase 3 mutant G133R in three Tunisian patients with 46, XY Disorders of Sex Development.
    Engeli RT; Rhouma BB; Sager CP; Tsachaki M; Birk J; Fakhfakh F; Keskes L; Belguith N; Odermatt A
    J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):147-54. PubMed ID: 26545797
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
    Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues.
    Qiu W; Zhou M; Labrie F; Lin SX
    Mol Endocrinol; 2004 Jul; 18(7):1798-807. PubMed ID: 15087468
    [TBL] [Abstract][Full Text] [Related]  

  • 99. 17β-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold.
    Wetzel M; Marchais-Oberwinkler S; Hartmann RW
    Bioorg Med Chem; 2011 Jan; 19(2):807-15. PubMed ID: 21211981
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity.
    Qiu W; Campbell RL; Gangloff A; Dupuis P; Boivin RP; Tremblay MR; Poirier D; Lin SX
    FASEB J; 2002 Nov; 16(13):1829-31. PubMed ID: 12223444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.